We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

16 hedge funds and large institutions have $53.2M invested in Trevi Therapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.36% more ownership

Funds ownership: 79.12% → 79.48% (+0.36%)

16% less capital invested

Capital invested by funds: $63.5M → $53.2M (-$10.3M)

20% less funds holding

Funds holding: 20 → 16 (-4)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
16
Holders Change
-4
Holders Change %
-20%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
+$281K
2
BlackRock
BlackRock
New York
+$23.2K
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$862

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$422K
2
TRCT
Tower Research Capital (TRC)
New York
-$11K
3
UBS Group
UBS Group
Switzerland
-$7K
4
Victory Capital Management
Victory Capital Management
Texas
-$4K
5
SSA
Schonfeld Strategic Advisors
New York
-$1.66K
Name Holding Trade Value Shares
Change 		Change in
Stake
TGHSA
1
TPG Group Holdings (SBS) Advisors
Texas
$23.7M – – –
NMC
2
NEA Management Company
Maryland
$16.7M – – –
OFM
3
Omega Fund Management
Massachusetts
$4.74M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$2.97M – – –
Franklin Resources
5
Franklin Resources
California
$2.2M -$422K -112,653 -16%
SSA
6
Schonfeld Strategic Advisors
New York
$632K -$1.66K -442 -0.3%
Vanguard Group
7
Vanguard Group
Pennsylvania
$564K – – –
DCM
8
Driehaus Capital Management
Illinois
$469K – – –
PCM
9
Pinz Capital Management
New York
$377K +$376K +100,355 New
BCM
10
Bridgeway Capital Management
Texas
$281K +$281K +75,000 New
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$228K +$862 +230 +0.4%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$155K – – –
Stifel Financial
13
Stifel Financial
Missouri
$91K -$49 -13 -0.1%
Northern Trust
14
Northern Trust
Illinois
$62K – – –
BlackRock
15
BlackRock
New York
$28K +$23.2K +6,185 +531%
PAM
16
Panagora Asset Management
Massachusetts
$2K – – –
TRCT
17
Tower Research Capital (TRC)
New York
– -$11K -2,344 Closed
UBS Group
18
UBS Group
Switzerland
– -$7K -1,577 Closed
Victory Capital Management
19
Victory Capital Management
Texas
– -$4K -986 Closed
Morgan Stanley
20
Morgan Stanley
New York
– -$1K -114 Closed

TRVI Hedge Fund Activity: Q4 2019 in Review

16 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q4 2019, worth a combined $53.2M — down 16% from $63.5M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of TRVI and 2 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $281K. The largest seller was Franklin Resources, cutting an estimated $422K.

  • 16 institutional investors held Trevi Therapeutics (TRVI) as of Q4 2019, down from 20 in Q3 2019.
  • Funds reported $53.2M of Trevi Therapeutics stock for Q4 2019, down 16% quarter-over-quarter.
  • 2 funds opened new Trevi Therapeutics positions in Q4 2019 and 6 closed out, a net change of -4 holders.
  • The largest Trevi Therapeutics buyer in Q4 2019 was Bridgeway Capital Management, an estimated $281K added.
  • The largest Trevi Therapeutics seller in Q4 2019 was Franklin Resources, an estimated $422K sold.

Based on aggregated 13F filings for Q4 2019.